Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if subjects with Parkinson's disease who are
experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary
excessive movements) would benefit from a higher dose of Requip as compared to the maximum
FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip
as used in this study is investigational, which means it has not been approved by the US Food
and Drug Administration (FDA) at this dose level.